InsidersTradesSigma
Track the NovaBay Pharmaceuticals, Inc. share price and the full insider trade history of the company, a listed issuer based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, NovaBay Pharmaceuticals, Inc. has logged 43 public disclosures. Market capitalisation: €51.9m. The latest transaction was filed on 29 January 2026 (Attribution). Among the most active insiders: Kunin Audrey. All data is free.
43
Insider Decl.
n/a
Thresholds
€454,154
20 ops.
Buy Volume
€140,913
8 ops.
Sell Volume
43Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 29 January 2026
Declarations43 total
6,388,000 sharesCommon StockSEC:0000921895-26-000165:0
56,806,080 shares0Common StockSEC:0001437749-25-032854:0
56,806,080 shares0Common StockSEC:0001437749-25-032855:0
56,806,080 shares0Common StockSEC:0001437749-25-032856:0
14,000 shares@ US$0.6313.2% of flowCommon Stock, par value $0.01 per shareSEC:0001398344-25-007144:0
Canonical exit: 16 Jun 2025 (T+90)
2,597 shares@ US$0.6352.6% of flowCommon Stock, par value $0.01 per shareSEC:0001398344-25-007136:0
Canonical exit: 4 May 2025 (T+90)
31,703 shares@ US$0.6934.1% of flowCommon Stock, par value $0.01 per shareSEC:0001398344-25-007133:0
Canonical exit: 27 Apr 2025 (T+90)
917 shares@ US$0.580.8% of flowCommon Stock, par value $0.01 per shareSEC:0001398344-25-007148:0
Canonical exit: 1 Jul 2025 (T+90)
13,292 shares@ US$0.60912.3% of flowCommon Stock, par value $0.01 per shareSEC:0001398344-25-007146:0
Canonical exit: 24 Jun 2025 (T+90)
25,033 shares@ US$0.619924.2% of flowCommon Stock, par value $0.01 per shareSEC:0001398344-25-007139:0
Canonical exit: 26 May 2025 (T+90)
14,645 shares@ US$0.5812.8% of flowCommon Stock, par value $0.01 per shareSEC:0001398344-25-007141:0
Canonical exit: 8 Jun 2025 (T+90)
858 sharesCommon StockSEC:0001437749-23-014701:0
858 sharesCommon StockSEC:0001437749-23-014700:0
858 sharesCommon StockSEC:0001437749-23-014705:0
858 sharesCommon StockSEC:0001437749-23-014704:0
1 shares@ US$1.810.0% of flowCommon StockSEC:0001437749-22-028673:0
1 shares@ US$1.810.0% of flowCommon StockSEC:0001437749-22-028672:0
5,960 shares@ US$2.10492.8% of flowCommon StockSEC:0001437749-22-028439:0
5,960 shares@ US$2.10492.8% of flowCommon StockSEC:0001437749-22-028438:0
5,960 shares@ US$2.10492.8% of flowCommon StockSEC:0001437749-22-028029:0
5,960 shares@ US$2.10492.8% of flowCommon StockSEC:0001437749-22-028031:0
291,368 shares@ US$0.158210.7% of flowCommon StockSEC:0001437749-22-022648:0
291,368 shares@ US$0.158210.7% of flowCommon StockSEC:0001437749-22-022646:0
25 of 43 declarations
关于 NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc. 是一家总部位于美国的医疗保健公司，在纽约证券交易所美国市场上市，属于更广泛的纽约证券交易所/纳斯达克小型股范畴。该公司总部位于加利福尼亚州埃默里维尔，其业务历来以围绕其专有的次氯酸平台构建的专业眼科、伤口护理和皮肤科产品为中心。随着时间的推移，NovaBay 建立了一个利基商业产品组合，其中包括 Avenova、NeutroPhase、PhaseOne 和 DERMAdoctor 护肤品牌。然而，在剥离关键运营资产后，该公司在 2024-2025 年经历了重大的战略调整。([sec.gov](https://www.sec.gov/Archives/edgar/data/1389545/000182912625007607/novabay_ars.pdf?utm_source=openai)) 从历史角度看，NovaBay 发展成为一家专注于未满足市场抗感染局部产品的专业医疗保健和生命科学公司，而非广泛的处方药。Avenova 是其旗舰眼部护理产品，定位为抗菌眼睑和睫毛喷雾；NeutroPhase 和 PhaseOne 针对伤口护理应用；DERMAdoctor 将业务扩展到护肤和美容领域。这种组合使 NovaBay 具有医疗产品和面向消费者的健康品牌混合的特征，但该公司仍然是一个规模有限、收入基础集中的小型商业平台。([novabay.com](https://novabay.com/pressreleases/novabay-pharmaceuticals-announces-new-partner-pharmacy-program/?utm_source=openai)) 从竞争角度来看，NovaBay 应被视为一家正在重新定位的微型市值公司，而非行业领导者。管理层强调基于专有、稳定形式的次氯酸的临床验证产品，但该公司在眼科、伤口护理和皮肤科领域面临来自规模更大、资金更雄厚的竞争对手。最近的美国证券交易委员会备案文件和公司披露显示，NovaBay 于 2025 年 1 月完成了 Avenova 的出售，随后披露了一项融资交易以及为维持上市地位而做出的更广泛努力，同时寻求未来的战略交易。这使得当前的股权故事更多地关乎公司结构、流动性和选择权，而非有机商业扩张。([sec.gov](https://www.sec.gov/Archives/edgar/data/1389545/000182912625007607/novabay_ars.pdf?utm_source=openai)) 从地理上看，NovaBay 扎根于加利福尼亚州埃默里维尔，其核心商业足迹一直在美国，尽管 DERMAdoctor 等较老的生产线通过包括北美、欧洲、亚洲和拉丁美洲在内的国际渠道分销。对于投资者而言，关键在于这不再是一个简单的增长型生物技术公司；它是一个具有较高执行风险、潜在稀释以及依赖治理和融资里程碑的重组情况。最近最重要的发展是资产出售、与 2025 年融资协议相关的领导层变动，以及公司声明支持其上市并准备潜在战略交易的意图。([sec.gov](https://www.sec.gov/Archives/edgar/data/0001389545/000182912625006520/novabay_ex99-1.htm?utm_source=openai))
